Anvisa, led by the Ministry of Health, has set percentages for raising the price of antibiotics, anti-inflammatory agents, diuretics, and other drugs. Homeopathic and naturopathic products are not subject to such price increase. The cap-price determined will be frozen either for a one-year period or until March 2014. According to the Brazilian Pharmaceutical Wholesalers Association (Abafarma), the percentages vary between 2.70%, 4.59%, and 6.31%, and were stipulated based on the market share of each product in the local market in comparison with generic brands of the same drug. As Abafarma executives note, the only products in Brazil to have price controls are pharmaceutical drugs.
Price-cap regulationSince 2003, Anvisa's regulatory chamber has managed price controls of pharmaceutical drugs commercialized in Brazil by setting price-cap standards. The "production" price-cap defines the maximum wholesale price at which a pharmaceutical drug may be sold in the Brazilian market, while the "consumer" price-cap is the maximum price at which it can be sold to the customer at drugstores and pharmacies around the country.
The regulatory authority defines the maximum price of pharmaceutical drugs through CMED's Resolution 2/2004. New drugs entering the market will be put in categories and priced according to their use and scientific evidence according to the regulatory authority. When considering the price-cap for new pharmaceutical products, the local authority will also evaluate the lowest international price for that product using certain countries as a parameter, including the country where the drug was produced, as well others such as the United States, Canada, Spain, Italy, Portugal, Greece, France, Australia, and New Zealand.